Daratumumab, the first anti-CD38 monoclonal antibody to be given approval both for patients with newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM), is now a backbone of MM patient management, having shown significant efficacy when combined with other standard anti-myeloma regimens [6,7,8]. This evidence concerns the gene CD38 and Miyoshi myopathy.